Important piece not merely on why companies should be talking with payers about Ph III trials — but specifically what in the trials they should be talking about. Quotes from our colleagues Jane F. Barlow, MD, MPH, MBA and Roger Longman help clarify the discussion.
read full article ›Wyden’s aren’t the only complaints about the accelerated approval program. Payers are increasingly concerned they’re not getting the data they need to evaluate the drugs and will increasingly ask companies with these approvals to risk-share on safety and efficacy. Even mid-size plans are getting into the act (via, for example, RE Marketplace)
read full article ›Come hear us share at the 2022 BIO International Convention, June 13-16, in San Diego, California
read full article ›While payers add and delete drugs from formularies for a variety of reasons (e.g., cost, PB vs MB, generics) patients pay the ultimate price – delays in treatment due to more onerous PA process and/or higher out-of-pocket costs. Notably UHC has excluded Rebif (MS) while CVS removed Aimovig (migraines) and Eliquis (blood thinner).
read full article ›On the front page of Drug Channels Institute today is Real Endpoints CEO, Jeff Berkowitz who introduces Real Endpoints' tech-enabled solution to the Medicare copay problem, RE Assist.
read full article ›Biotech stocks are a mess — but the stock of skilled execs, particularly in Boston, is sky high. And judging from how often we’re asked to suggest market-access candidates, the demand for execs who understand reimbursement is white hot.
read full article ›The Digital Therapeutics Alliance has released an updated guide to the International DTx Regulatory & Reimbursement Pathways for 8 major markets, including the US (which desperately needs to accelerate coverage and adoption of innovative treatments in areas of unmet need).
read full article ›Thank you to all of the donors who have helped keep the nation's blood supply ready when needed. Learn more about how you are helping your community at www.bloodcenter.org!
read full article ›The write-ups of the Illumina JPM talk, all highlighting progress with coverage of oncology testing, missed one crucial point: the big research deal with a new United/Optum unit (Optum Evidence Engine). In Dx — given next-gen and WG sequencing VBA deals with Harvard Pilgrim Health Care (Point32Health) — Illumina clearly seems to be the leader in proving, and then standing behind, both clinical and economic utility of testing.
read full article ›